Abstract
Six subjects each smoked a 1% marijuana cigarette and 2 hr later smoked a second one. Plasma levels of delta-9-tetrahydrocannabinol were measured for 9 hr with a radioimmunoassay. Heart rate and self-reported “high” were measured for 2 hr after each cigarette. All three measures showed a rapid increase after the start of smoking with Cmax occurring before the end of smoking. There was a strong correlation between decrease in heart rate and plasma levels from 10 min after smoking until 120 min. All pharmacodynamic response measures returned to baseline values within approximately 2 hr.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
C. E. Turner, M. A. Elsohly, and E. G. Boeren. Constituents of cannabis sativa L. XVI: a review of the natural constituents.J. Natural Products 43:169–234 (1980).
R. C. Petersen, (ed.),Marijuana Research Findings: 1980. U.S. Government Printing Office, Washington, D.C., National Institute on Drug Abuse, DHHS Publication (ADM) 80–1001 (1980).
M. Perez-Reyes, S. M. Owens, and S. DiGuiseppi. The clinical pharmacology and dynamics of marijuana cigarette smoking.J. Clin. Pharmacol. 21:201S-207S (1981).
J. H. Holley, K. W. Hadley, and C. E. Turner. Constituents of cannabis sativa L. XI: Cannabidiol and cannabichromene in samples of known geographic origin.J. Pharm. Sci. 64:892–895 (1975).
S. M. Owens, A. J. McBay, H. M. Reisner, and M. Perez-Reyes. 125-I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method.Clin. Chem. 27:619–624 (1981).
M. Berman and M. F. Weiss.Users Manual for Simulation Analysis and Modeling. National Institutes of Health, DHEW (1977).
C. A. Hunt, R. T. Jones, R. I. Herning, and J. Bachman. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.J. Pharmacokin. Biopharm. 9:245–260 (1981).
C. A. Hunt and R. T. Jones. Tolerance and disposition of tetrahydrocannabinol in man.J. Pharm. Exp. Ther. 215:35–44 (1980).
A. Ohlsson, J. E. Lindgren, A. Wahlen, S. Agurell, L. E. Hollister, and H. K. Gillespie. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effect after oral and intravenous administration and smoking.Clin. Pharmacol. Ther. 28:409–416 (1980).
J. E. Lindgren, A. Ohlsson, S. Agurell, L. E. Hollister, and H. K. Gillespie. Clinical effects and plasma levels of delta-9-tetrahydrocannabinol in heavy and light users of cannabis.Psychopharmacology 74:208–212 (1981).
A. Ohlsson, J. E. Lindgren, A. Wahlen, S. Agurell, L. E. Hollister, and H. K. Gillespie. Single dose kinetics of deuterium labeled delta-9-tetrahydrocannabinol in heavy and light cannabis users.Biomed. Mass Spectrom. 9:6–10 (1982).
S. Agurell, J. E. Lindgren, A. Ohlsson, H. Gillespie, and L. E. Hollister. Interactions of delta-1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.Experientia 37:1090–1091 (1981).
M. M. Halldin, S. Carlsson, S. L. Kanter, M. Widman, and S. Agurell. Urinary metabolites of delta-1-tetrahydrocannabinol in man.Arzneim.-Forsch./Drug Res. 32:764–768 (1982).
M. M. Halldin, L. K. R. Andersson, M. Widman, and L. E. Hollister. Further urinary metabolites of delta-1-tetrahydrocannabinol in man.Arzneim.-Forsch./Drug Res. 32:1135–1138 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barnett, G., Chiang, C.W.N., Perez-Reyes, M. et al. Kinetic study of smoking marijuana. Journal of Pharmacokinetics and Biopharmaceutics 10, 495–506 (1982). https://doi.org/10.1007/BF01059033
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059033